VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

Abstract Background Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bev...

Full description

Bibliographic Details
Main Authors: Maurizio Martini, Ivana de Pascalis, Quintino Giorgio D’Alessandris, Vincenzo Fiorentino, Francesco Pierconti, Hany El-Sayed Marei, Lucia Ricci-Vitiani, Roberto Pallini, Luigi Maria Larocca
Format: Article
Language:English
Published: BMC 2018-05-01
Series:BMC Cancer
Subjects:
Recurrent glioblastoma
Antiangiogenetic-therapy
VEGF isoforms
Target therapy
Online Access:http://link.springer.com/article/10.1186/s12885-018-4442-2

Internet

http://link.springer.com/article/10.1186/s12885-018-4442-2

Similar Items